ArticleEvolutionary applications2015
Understanding genetic variation in in vivo tolerance to artesunate: implications for treatment efficacy and resistance monitoring.
Article in Evolutionary applications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Targeting malaria parasites inside mosquitoes: ecoevolutionary consequences.Trends in parasitology · 2022Review
- The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistantEvolutionary applications · 2018Article
- Facilitation through altered resource availability in a mixed-species rodent malaria infection.Ecology letters · 2016Article
- Predicting optimal transmission investment in malaria parasites.Evolution; international journal of organic evolution · 2016Article
- A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections.Evolution, medicine, and public health · 2016Article
- Genetically Determined Response to Artemisinin Treatment in Western Kenyan Plasmodium falciparum Parasites.PloS one · 2016Article
- Within-host dynamics of infection: from ecological insights to evolutionary predictions.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Article
- Fighting microbial drug resistance: a primer on the role of evolutionary biology in public health.Evolutionary applications · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Artemisinin-based drugs are the front-line weapon in the treatment of human malaria cases, but there is concern that recent reports of slow clearing infections may signal developing resistance to treatment. In the absence of molecular markers for resistance, current efforts to monitor drug efficacy are based on the rate at which parasites are cleared from infections. However, some knowledge of the standing variation in parasite susceptibility is needed to identify a meaningful increase in infection half-life. Here, we show that five previously unexposed genotypes of the rodent malaria parasite Plasmodium chabaudi differ substantially in their in vivo response to treatment. Slower clearance rates were not linked to parasite virulence or growth rate, going against the suggestion that drug treatment will drive the evolution of virulence in this system. The level of variation observed here in a relatively small number of genotypes suggests existing 'resistant' parasites could be present in the population and therefore, increased parasite clearance rates could represent selection on pre-existing variation rather than de novo resistance events. This has implications for resistance monitoring as susceptibility may depend on evolved traits unrelated to drug exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.